A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
LymphomaNon-Hodgkin9 moreThis is a Phase I/II multicentre, open-label trial designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel chimeric antigen receptor (CAR) T-cell engager, ALETA-001, administered by intravenous (IV) infusion as a single agent every 2 weeks in patients with relapsed non-Hodgkin lymphoma (NHL) who have failed to optimally respond to prior treatment with anti-CD19 CAR T-cell therapy. This first in human study is divided into 2 parts: a safety lead-in phase (Phase I) and a dose expansion phase (Phase II). Different dose levels of ALETA-001 will be evaluated in Phase I in order to define a recommended dosing level and schedule for Phase II. Phase II will further evaluate the safety, PK and therapeutic activity of ALETA-001.
Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
Diffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma RefractoryThis is a prospective, single center, single arm, open label study of zanubrutinib, lenalidomide in combination with Rituximab-ICE for treatment of relapsed/refractory diffuse large B-cell lymphoma.
A Phase 2 Study of CRG-022 in Participants With Relapsed/Refractory Large B-cell Lymphoma
CancerRelapsed/Refractory Large B-cell Lymphoma (LBCL)This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy for the treatment of relapsed or refractory large B-cell lymphoma.
Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL
Diffuse Large B Cell LymphomaNational, multicenter, non-randomized, retrospective observational study (Real World Evidence-RWE) to analyze the epidemiological profile of diffuse large B cell lymphoma, clinical management, treatment in molecular subgroups, progression profile and patient survival outcomes enrolled and treated within the last 6 years (2017 to 2022), in national cancer reference centers.
Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation...
Diffuse Large B Cell LymphomaThis single-center, randomized clinical study will evaluate the efficacy and safety of Venetoclax combined with BEAM Pretreatment Regimen in ASCT treatment of DLBCL patients.
Pembro Plus CAR T-cell Therapy in R/R in PMBCL
Primary Mediastinal Large B-cell Lymphoma (PMBCL)Primary Mediastinal Large B Cell Lymphoma4 moreThis research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal B-cell lymphoma that has recurred after prior treatment. The names of the study drugs involved in this study are: - Pembrolizumab Standard treatment will include: CAR T-cell therapy (either axicabtagene-ciloleucel or lisocabtagene maraleucel) Cyclophosphamide Fludarabine
Retreatment With CTL019/CTL119
LymphomaB-CellThis research study is designed to evaluate the effects of retreatment with CTL019/CTL119 in patients with late relapse of B-cell lymphomas.
Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large...
Diffuse Large B Cell LymphomaRelapsed Non Hodgkin Lymphoma1 moreThis phase II clinical trial aims at evaluating the efficacy and safety of azacitidine followed by rituximab-GDP immunochemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients who were treated with from 1 to 4 lines of prior therapies for relapsed/refractory DLBCL wee eligible. azacitidine will be treated one week prior to conventional rituximab-gemcitabine, dexamethasone, cisplatin (R-GDP) immunochemotherapy. Patients will be treated every 21 days as one cycle, and up to 6 cycles. The primary endpoint of this study is objective response rate according to the Lugano response criteria for non-Hodgkin lymphoma, and secondary endpoints are safety, complete response, progression-free survival, and overall survival.
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
Diffuse Large B Cell LymphomaCAR-T2 moreThis is a single-arm single center study to prospectively evaluate the safety and efficacy of ultra-fraction radiotherapy bridging CAR-T therapy in relapsed/refractory diffuse large b cell lymphoma
CD19 CAR-T Therapy for Elderly Patients With B-cell Non-Hodgkin's Lymphoma
Non-hodgkin Lymphoma,B CellA Study of CD19 CAR-T Therapy for Elderly Patients With B-cell Non-Hodgkin's Lymphoma.